

CURRICULUM VITAE

FORMATO
EUROPEO PER IL
CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome e Cognome
Incarico attuale
Profilo breve

Albulena Bajrami
Dirigente Medico Neurologia
Mi occupo delle patologie neurologiche con particolare interesse per le malattie infiammatorie - autoimmuni come la sclerosi multipla. Principale occupazione nel Day Hospital di Neurologia e ambulatorio sclerosi multipla.

ISTRUZIONE
E FORMAZIONE

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Qualifica conseguita
- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Qualifica conseguita
- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Qualifica conseguita

01.11.2018-11.11.2022
Neurologia Ospedale Universitario Integrato di Verona
Specializzazione in Neurologia
01.11.2021-30.11.22
Progetto di Ricerca presso università di Amsterdam, dipartimento di Anatomia con titolo del progetto “Functional-MRI network reactions to cortical pathology”, sotto la supervisione di prf. Menno Schoonheim
25.09.17-25.10.17
Frequentazione clinica presso **reparto di Neurologia Ospedale Charing Cross di Londra** con tutor prof Richard Nicholas e dr. Antonio Scalfari
01.08.17-31.08.17
Frequentazione clinica presso **reparto di Neurologia all’ospedale Santa Maria di Lisbona** con progetto SISM (società italiana degli studenti di medicina).
18.07.2017
Scuola di Medicina e Chirurgia Università degli studi di Verona
Laurea magistrale in Medicina e Chirurgia
01.09.2015-01.03.2015
Università di Medicina a Cardiff (UK)
ERASMUS, conseguimento di esami OSCE: Neurologia, Ginecologia, Pediatria, Psichiatria
ALBULENA BAJRAMI

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Qualifica conseguita

ESPERIENZA LAVORATIVA

- Date (da – a)
- Tipo di impiego
- Principali mansioni e responsabilità

MADRELINGUA

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

PUBBLICAZIONI

2011
Liceo Scientifico Galileo Galilei

Diploma Liceo Scientifico

04.01.2023-IN CORSO
Dirigente medico in Neurologia
Gestione Day Hospital di Neurologia, ambulatorio sclerosi multipla.

Italiana

INGLESE
ECCELLENTE
ECCELLENTE
ECCELLENTE

1. Krijnen EA, van Dam M, **Bajrami A**, Bouman PM, Noteboom S, Barkhof F, Uitdehaag BMJ, Steenwijk MD, Klawiter EC, Koubiyr I, Schoonheim MM. *Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex*. Ann Clin Transl Neurol. 2025 Jan;12(1):121-136.
2. Ziccardi S, Crescenzo F, Guandalini M, Caliskan G, Martinelli L, Tamanti A, Schiavi GM, **Bajrami A**, Marastoni D, Calabrese M. *Early regional cerebral grey matter damage predicts long-term cognitive impairment phenotypes in multiple sclerosis: a 20-year study*. Brain Commun. 2024 Oct 12;6(6):fcae355.
3. Bontempi P, Marangoni S, Cazzoletti L, **Bajrami A**, Giometto B, Farace P, Rozzanigo U. *Very-long T2-weighted imaging of the non-lesional brain tissue in multiple sclerosis patients*. NMR Biomed. 2024 Dec;37(12):e5235
4. Krijnen EA, Broeders TAA, Noteboom S, van Dam M, **Bajrami A**, Bouman PM, Barkhof F, Uitdehaag BMJ, Klawiter EC, Koubiyr I, Schoonheim MM. *The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis*. J Neurol. 2024 Jun;271(6):3203-3214.
5. Marastoni D, Foschi M, Eccher C, Crescenzo F, Mazziotti V, Tamanti A, **Bajrami A**, Camera V, Ziccardi S, Guandalini M, Bosello F, Anni D, Virla F, Turano E, Romoli M, Mariotti R, Pizzini FB, Bonetti B, Calabrese M. *CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis*. Front Immunol. 2024 Feb 9;15:1343892.
6. **Bajrami A**, Tamanti A, Peloso A, Ziccardi S, Guandalini M, Calderone M, Castellaro M, Pizzini FB, Montemezzi S, Marastoni D, Calabrese M. *Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis*. J Neurol. 2024 May;271(5):2149-2158.
7. Noteboom S, van Nederpelt DR, **Bajrami A**, Moraal B, Caan MWA, Barkhof F, Calabrese M, Vrenken H, Strijbis EMM, Steenwijk MD, Schoonheim MM. *Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR*. J Neurol. 2023 Nov;270(11):5201-5210

8. **Bajrami A**, Magliozzi R, Pisani AI, Pizzini FB, Crescenzo F, Marastoni D, Calabrese M. Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. *Mult Scler*. 2022 Apr;28(4):550-560
9. **Bajrami A**, Zivelonghi C, Micheletti N, Cappellari M. Artery of Percheron stroke from carotid lesion. *Neurol Sci*. 2021 Nov;42(11):4807-4808.
10. Boscolo Galazzo I, Brusini L, Akinci M, Cruciani F, Pitteri M, Ziccardi S, **Bajrami A**, Castellaro M, Salih AMA, Pizzini FB, Jovicich J, Calabrese M, Menegaz G. Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing-Remitting Multiple Sclerosis Phenotypes. *J Magn Reson Imaging*. 2022 Jan;55(1):154-163
11. Magliozzi R, Scalfari A, Pisani AI, Ziccardi S, Marastoni D, Pizzini FB, **Bajrami A**, Tamanti A, Guandalini M, Bonomi S, Rossi S, Mazziotti V, Castellaro M, Montemezzi S, Rasia S, Capra R, Pitteri M, Romualdi C, Reynolds R, Calabrese M. The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. *Ann Neurol*. 2020 Sep;88(3):562-573
12. **Bajrami A**, Pitteri M, Castellaro M, Pizzini F, Romualdi C, Montemezzi S, Monaco S, Calabrese M. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients. *J Neurol*. 2018 Sep;265(9):2154-2161.
13. Pitteri M, Magliozzi R, **Bajrami A**, Camera V, Calabrese M. Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables. *Expert Opin Pharmacother*. 2018 Mar;19(4):387-395.
14. Calabrese M, Pitteri M, Farina G, **Bajrami A**, Castellaro M, Magliozzi R, Monaco S. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. *J Neurol Neurosurg Psychiatry*. 2017 Dec;88(12):1073-1078.

STUDI IN CORSO

Luglio 2024-in corso: An Italian observational, multicente, 12-month, single-arm study to evaluate the effectiveness and safety of treatment with ofatumumab (Kesimpta) in a population of RRMS patients in the real world setting.

PARTECIPAZIONE A CORSI DI FORMAZIONE

16-19 gennaio 2024 2nd ECTRIMS Winter School 2024 “ Body Fluid Biomarkers in diagnosis, management and research of MS: from Bnech to Bedside”

7-8 Giugno 2022 e 27-29 settembre 2022. Internation MRI-lab- A journey from the basics to advanced methodologies of MRI

RELATORE AD EVENTI

05.12.2024-06.12.2024: Perspectives in MS 2024. Nuove prospettive di cura per il paziente con SM

11.10.24 La genitorialità nella sclerosi multipla

15.03.24 e 10.06.24 Le malattie demielinizzanti: diagnosi differenziale tra SM, NMOSD, MOGAD e la loro terapia precoce

15.12.23 L'importanza del monitoraggio del paziente MS trattato con HET mediante MRI

03.03.23 e 21.04.2023 Improve SM 2023

26.09.23 Individuazione precoce della progressione in SM: counseling e management del paziente SPMS

PRESENTAZIONE ORALE

03.12.22 – 06.12.22 PRESENTAZIONE ORALE, 52° CONGRESSO SOCIETÀ ITALIANA DI NEUROLOGIA (SIN), Milano, Italia. “Non-random localization of cortical lesions in functional Networks is related to cognitive and physical impairment in multiple sclerosis.” A. Bajrami, E. Krijnen, T. Broeders, P. Bouman, M. Van Dam, E. Klawiter, B. Uitdehaag, I. Koubiyr, M. Calabrese, M. Schoonheim. *Neurological Sciences* (2022) 43 (Suppl 1):S1–S530, S441

18.05.22-19.05.22 PRESENTAZIONE ORALE, IMSCOG Annual Meeting 2022, Bordeaux: "Distribution of cortical lesions across functional networks is non-random and related to cognitive impairment" Bajrami A, Krijnen EA, Broeders TAA, Bouman PM, Dam van M, Klawiter EC, Uitdehaag BMJ, Calabrese M, Koubiyr I, Schoonheim MM

03.10.21-07.10.21 PRESENTAZIONE ORALE, XXV World Congress of Neurology Secretariat: "CSF inflammatory profile in clinically isolated syndrome and definite multiple sclerosis." Bajrami, A., Magliozzi, R., Pezzini F., Pisani, Marastoni, D., Calabrese, M. Journal of the Neurological Sciences, Volume 429, pp 117792, 01.10.2021

16.09.21-17.09.21 PRESENTAZIONE ORALE, international congress "The silent disease activity in Multiple Sclerosis: molecular and imaging biomarkers", Riva del Garda: "CSF inflammatory profile in clinically isolated syndrome and definite multiple sclerosis." Bajrami, A., Magliozzi, R., Pezzini F., Pisani, Marastoni, D., Calabrese, M.

27.11.20-31.11.20 PRESENTAZIONE ORALE, Virtual Italian Society of Neurology (SIN) Meeting: "Cortical and deep grey matter volume loss is specifically linked to cerebrospinal fluid inflammation in early multiple sclerosis." Bajrami, A., Magliozzi, R., Pisani, A.I., Crescenzo, F., Marastoni, D., Calabrese, M.

PRESENTAZIONE POSTER

First author, e-POSTER, ECTRIMS 2024, Copenhagen, Denmark, Poster title: "Natalizumab-associated primary central nervous system lymphoma" A. Bajrami, F.Boso, S.Marangoni

First author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Distribution of cortical lesions across functional networks is non-random and related to cognitive impairment" A. Bajrami, E. Krijnen, T. Broeders, P. Bouman, M. Van Dam, E. Klawiter, B. Uitdehaag, I. Koubiyr, M. Calabrese, M. Schoonheim. Multiple Sclerosis Journal, Volume 28, Page 275-276, 2022/10/01

First author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Ocrelizumab reduces focal lesions and global/regional volume changes if compared to other second-line treatment." A Bajrami, A. Tamanti, A. Peloso, A Colombi, M Castellaro, D Marastoni, M Calabrese. Multiple Sclerosis Journal, Volume 28, Num 3_SUPPL, Page 1017-1017, 2022/10/01

Co-author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Feasibility of detecting atrophy relevant for disability and cognition on 3D-FLAIR" S Noteboom, MD Steenwijk, DR van Nederpelt, EMM Strijbis, A Bajrami, B Moraal, MWA Caan, F Barkhof, H Vrenken, MM Schoonheim. Multiple Sclerosis Journal, Volume 28, Num 3_SUPPL, Page 270-271, 2022/10/01

Co-author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Regional altered diffusion in lesional and normal-appearing cortex is linked to cognitive impairment in multiple sclerosis" EA Krijnen, A Bajrami, TA Broeders, S Noteboom, PM Bouman, BM Uitdehaag, EC Klawiter, I Koubiyr, MM Schoonheim. Multiple Sclerosis Journal, Volume 28, Num 3_SUPPL, Page 535-536, 2022/10/01

Co-author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Cortical lesions in functional networks are related to cortical atrophy, but only in normal-appearing grey matter" EA Krijnen, A Bajrami, M Van Dam, PM Bouman, S Noteboom, BM Uitdehaag, EC Klawiter, I Koubiyr, MM Schoonheim. Multiple Sclerosis Journal, Volume 28, Num 3_SUPPL, Page 536-536, 2022/10/01

Co-author, POSTER, ECTRIMS 2022, Amsterdam, Netherlands, Poster title: "Early cortical and deep gray matter atrophy predicts disability progression independent of relapse in multiple sclerosis: a 17 year longitudinal study" D Marastoni, A Bajrami, AI Pisani, E Colato, G Schiavi, S Ziccardi, A Colombi, M Guandalini, A Peloso, A Tamanti, A Scalfari, M Calabrese. Multiple Sclerosis Journal, Volume 28, Num 3_SUPPL, Page 171-171, 2022/10/01
First author, POSTER, ECTRIMS 2021, the digital experience. Poster title: "CSF inflammatory profile in clinically isolated syndrome and definite multiple sclerosis." Bajrami, A., Magliozzi, R., Pezzini F., Pisani, Marastoni, D., Calabrese, M.

First author, POSTER, XXV World Congress of Neurology Secretariat. Poster title: "Artery of Percheron stroke from carotid lesion." Bajrami A, Zivelonghi C, Micheletti N, Cappellari M.

First author, POSTER, MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting: Poster title: "Cortical and deep grey matter volume loss is specifically linked to cerebrospinal fluid inflammation in early multiple sclerosis." Bajrami, A., Magliozzi, R., Pisani, A.I., Crescenzo, F., Marastoni, D., Calabrese, M. Multiple Sclerosis Journal, Volume 26, 3_SUPPL, Pagine 83-83, 2020/12/1

First author, POSTER, Italian Society of Neurology (SIN) Meeting, Bologna, Italy. Poster title: "Early diagnosis of Lyme neuroborreliosis with CXCL13 Latera Flow Immunoassay: a case report." Bajrami, A., Collini, L., Cainelli, L., Chiusole, M., Giometto, B.

Co-author, POSTER, Ectrims 2019, Stokhol, Sweden. Poster title: Intrathecal inflammatory profile predicts disease course in multiple sclerosis: a 4-year longitudinal study. M Calabrese, A Pisani, S Ziccardi, FB Pizzini, A Bajrami, A Tamanti, M Guandalini, S Bonomi, S Rossi, V Mazziotti, S Montemezzi, C Zuco, F Crescenzo, D Marastoni, M Pitteri, A Scalfari, C Romualdi, R Reynolds, R Magliozzi. Multiple Sclerosis Journal, Volume 25, Pagine 274-274, 2019/09/01

First author, POSTER, Annual Meeting European Charcot Foundation, Baveno, Italy. Poster title: "The effect of Gylenia on grey matter damage in RRMS patients". Bajrami, A., Pitteri, M., Castellaro, M., Pizzini, F., Romualdi, C., Montemezzi, S., Monaco, S., & Calabrese, M.

First author, POSTER, 7th joint ECTRIMS-ACTRIMS congress in Paris, France. Poster title: "The effect of fingolimod on focal and diffuse grey matter damage in active MS patients' A Bajrami, M Pitteri, S Ziccardi, D Marastoni, F Crescenzo, M Castellaro, S Rossi, R Magliozzi, S Monaco, M Calabrese. Multiple Sclerosis Journal, Volume 23, Pagine 620-621, 2017/10/1

Co-author, POSTER, 7th joint ECTRIMS-ACTRIMS congress in Paris, France. Poster title: "Cognitive assessment should be considered in clinical trials in association with other clinical outcome measures" S Ziccardi, M Pitteri, M Guandalini, C Zuco, A Bajrami, D Marastoni, F Crescenzo, R Magliozzi, S Rossi, M Castellaro, S Monaco, M Calabrese Multiple Sclerosis Journal, Volume 23, Pagine 576-576, 2017/10/1